Evidence map›Paper›PMID 31840094›Full record

ArticleNPJ digital medicine2019

Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis.

Tanuja Chitnis, Bonnie I Glanz, Cindy Gonzalez, Brian C Healy, Taylor J Saraceno, Neda Sattarnezhad, Camilo Diaz-Cruz, Mariann Polgar-Turcsanyi, Subhash Tummala, Rohit Bakshi and 33 more

Open access · goldAbstract read
In one paragraph

Article in NPJ digital medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability.Annals of clinical and translational neurology · 2026
    Trial
  3. A smartphone sensor-based digital outcome assessment of multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022
    Trial
  4. Sensors in Multiple Sclerosis.Current neurology and neuroscience reports · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 3 institutions in 1 country.

Tanuja Chitnis1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.ORCID 0000-0002-9897-4422
Bonnie I Glanz1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.
Cindy Gonzalez1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.
Brian C Healy1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.
Taylor J Saraceno1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.
Neda Sattarnezhad1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.
Camilo Diaz-Cruz1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.
Mariann Polgar-Turcsanyi1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.
Subhash Tummala1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.
Rohit Bakshi1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.ORCID 0000-0001-8601-5534
Vikram S BajajVerily Life Sciences, South San Francisco, CA USA.
David Ben-ShimolVerily Life Sciences, South San Francisco, CA USA.
Nikhil BikhchandaniVerily Life Sciences, South San Francisco, CA USA.
Alexander W BlockerVerily Life Sciences, South San Francisco, CA USA.ORCID 0000-0002-7486-9919
Joshua BurkartVerily Life Sciences, South San Francisco, CA USA.
Raphael CendrillonVerily Life Sciences, South San Francisco, CA USA.ORCID 0000-0002-4895-9056
Michael P CusackVerily Life Sciences, South San Francisco, CA USA.
Emre DemiralpVerily Life Sciences, South San Francisco, CA USA.
Sarel Kobus JoosteVerily Life Sciences, South San Francisco, CA USA.
Alaa KharbouchVerily Life Sciences, South San Francisco, CA USA.
Amy A LeeVerily Life Sciences, South San Francisco, CA USA.
Joseph LehárVerily Life Sciences, South San Francisco, CA USA.ORCID 0000-0001-7743-4366
Manway LiuVerily Life Sciences, South San Francisco, CA USA.
Swaminathan MahadevanVerily Life Sciences, South San Francisco, CA USA.
Mark MurphyVerily Life Sciences, South San Francisco, CA USA.
Linda C NortonVerily Life Sciences, South San Francisco, CA USA.
Tushar A ParlikarVerily Life Sciences, South San Francisco, CA USA.
Anupam PathakVerily Life Sciences, South San Francisco, CA USA.
Ali ShoebVerily Life Sciences, South San Francisco, CA USA.
Erin SoderbergVerily Life Sciences, South San Francisco, CA USA.
Philip StephensVerily Life Sciences, South San Francisco, CA USA.
Aaron H StoertzVerily Life Sciences, South San Francisco, CA USA.
Florence ThngVerily Life Sciences, South San Francisco, CA USA.
Kashyap TumkurVerily Life Sciences, South San Francisco, CA USA.ORCID 0000-0002-4561-8440
Hongsheng WangVerily Life Sciences, South San Francisco, CA USA.
Jane Rhodes3Biogen, Boston, MA USA.
Richard A Rudick3Biogen, Boston, MA USA.
Richard M Ransohoff3Biogen, Boston, MA USA.
Glenn A Phillips3Biogen, Boston, MA USA.
Effie Bruzik3Biogen, Boston, MA USA.
William J MarksVerily Life Sciences, South San Francisco, CA USA.
Howard L Weiner1Ann Romney Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, MA USA.
Thomas M SnyderVerily Life Sciences, South San Francisco, CA USA.
Veracyte (United States) · USBrigham and Women's Hospital · USBiogen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Technological advances in passive digital phenotyping present the opportunity to quantify neurological diseases using new approaches that may complement clinical assessments. Here, we studied multiple sclerosis (MS) as a model neurological disease for investigating physiometric and environmental signals. The objective of this study was to assess the feasibility and correlation of wearable biosensors with traditional clinical measures of disability both in clinic and in free-living in MS patients. This is a single site observational cohort study conducted at an academic neurological center specializing in MS. A cohort of 25 MS patients with varying disability scores were recruited. Patients were monitored in clinic while wearing biosensors at nine body locations at three separate visits. Biosensor-derived features including aspects of gait (stance time, turn angle, mean turn velocity) and balance were collected, along with standardized disability scores assessed by a neurologist. Participants also wore up to three sensors on the wrist, ankle, and sternum for 8 weeks as they went about their daily lives. The primary outcomes were feasibility, adherence, as well as correlation of biosensor-derived metrics with traditional neurologist-assessed clinical measures of disability. We used machine-learning algorithms to extract multiple features of motion and dexterity and correlated these measures with more traditional measures of neurological disability, including the expanded disability status scale (EDSS) and the MS functional composite-4 (MSFC-4). In free-living, sleep measures were additionally collected. Twenty-three subjects completed the first two of three in-clinic study visits and the 8-week free-living biosensor period. Several biosensor-derived features significantly correlated with EDSS and MSFC-4 scores derived at visit two, including mobility stance time with MSFC-4 z-score (Spearman correlation -0.546;

Indexed as

Multiple sclerosisSensors and probes

Identifiers

PMID31840094
PMCPMC6906296
OpenAlexW2996276198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.